Immuneering News

Buy Rating Affirmed for Immuneering With $8 Price Target Amidst Promising Pipeline and Upcoming Data Events

TipRanksMay 16 04:35 ET

Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)

TipRanksMay 13 07:55 ET

Immuneering Analyst Ratings

BenzingaMay 8 05:57 ET

Buy Rating Maintained for Immuneering Amid Promising Clinical Pipeline Developments

TipRanksMay 8 05:25 ET

Buy Rating Affirmed: Immuneering's Lead Asset IMM-1-104 Shows Promise Despite Market Skepticism

TipRanksMay 2 03:25 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)

TipRanksApr 12 06:30 ET

Immuneering Analyst Ratings

BenzingaApr 12 06:31 ET

Immuneering Analyst Ratings

BenzingaApr 2 07:49 ET

Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence

TipRanksMar 29 04:26 ET

Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TipRanksMar 19 01:40 ET

Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16

MT NewswiresMar 15 10:07 ET

Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating

MT NewswiresMar 15 08:13 ET

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Afya (AFYA) and Urogen Pharma (URGN)

TipRanksMar 15 07:50 ET

Analysts Are Bullish on These Healthcare Stocks: 2seventy Bio (TSVT), Immuneering (IMRX)

TipRanksMar 15 07:00 ET

Immuneering: Hold Rating Amidst Potential and Uncertainties in Drug Efficacy

TipRanksMar 15 06:46 ET

Immuneering Analyst Ratings

BenzingaMar 14 16:08 ET

Immuneering Analyst Ratings

BenzingaMar 11 10:37 ET

Immuneering's IMM-1-104 Progress Garners Buy Rating Amid Favorable Phase 2 Dose Determination and Anticipated Phase 1 Data

TipRanksMar 11 10:05 ET

Immuneering Analyst Ratings

BenzingaMar 5 07:55 ET

Oppenheimer Reiterates Outperform on Immuneering, Maintains $25 Price Target

BenzingaMar 5 07:56 ET